SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates

Key Points

• SAB Biotherapeutics met earnings expectations, reporting a quarterly loss of $0.28 per share. However, its net loss widened to $22.5 million as research and development costs increased to $16.2 million.
• Clinical progress remains a key focus: SAFEGUARD enrollment is accelerating across more than 60 sites, with completion targeted for Q4 2026 and top-line data expected in the second half of 2027. A grant will also support the planned Phase III PRISE-hATG study, expected to begin enrollment in the second half of 2026.
• The company ended the quarter with $208 million in cash, equivalents, and investments, providing an operating runway through 2028. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $12, well above the reported trading price of $3.85.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.28), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics' conference call:

• SAFEGUARD enrollment is accelerating, with more than 60 sites actively recruiting and increased screening and randomization. Management remains on track to complete enrollment in Q4 2026, with top-line data expected in the second half of 2027.
• Breakthrough T1D awarded a grant supporting the PRISE-hATG Phase III study, which is expected to begin enrollment in the second half of 2026 across seven sites. If successful, the study could support a future SAB-142 label expansion for patients treated up to two years after diagnosis, with top-line data expected in Q1 2029.
• SAB Bio ended the quarter with $208 million in cash, cash equivalents, and investments, providing an operating runway through 2028. However, higher clinical-development and headcount costs drove R&D expense to $16.2 million and the net loss to $22.5 million, versus $10.1 million a year earlier.
• Management views the recent FDA approval of Tzield in recently diagnosed Stage 3 Type 1 diabetes as validation that C-peptide can support an accelerated-approval pathway. SAB Bio also highlighted SAB-142’s potential competitive advantages, including two-day dosing and low to no immunogenicity that may enable redosing.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS traded up $0.08 during trading hours on Thursday, reaching $3.85. The stock had a trading volume of 279,785 shares, compared to its average volume of 683,940. The stock has a market cap of $294.39 million, a P/E ratio of -1.82 and a beta of 0.53. The stock has a 50 day simple moving average of $3.68 and a 200 day simple moving average of $3.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. SAB Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $5.15.

Institutional Investors Weigh In On SAB Biotherapeutics

Large investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in SAB Biotherapeutics in the 4th quarter valued at about $34,000. State Street Corp bought a new position in SAB Biotherapeutics during the fourth quarter worth about $49,000. ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics in the third quarter worth about $30,000. Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics in the third quarter worth about $32,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $74,000. Hedge funds and other institutional investors own 7.82% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reiterated a "sell (d+)" rating on shares of SAB Biotherapeutics in a report on Wednesday, July 8th. Barclays started coverage on SAB Biotherapeutics in a research note on Wednesday, June 24th. They issued an "overweight" rating and a $13.00 price objective for the company. Wall Street Zen cut SAB Biotherapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday. Leerink Partners boosted their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, June 15th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source